ArticleEBioMedicine2019
Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Article
- Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review.Translational gastroenterology and hepatology · 2022Review
- Network analysis of hepatocellular carcinoma liquid biopsies augmented by single-cell sequencing data.Frontiers in genetics · 2022Article
- Pathway-Based Personalized Analysis of Pan-Cancer Transcriptomic Data.Biomedicines · 2021Article
- Highly accurate diagnosis of papillary thyroid carcinomas based on personalized pathways coupled with machine learning.Briefings in bioinformatics · 2021Article
- Article
- Article
- Molecular Subclassification Based on Crosstalk Analysis Improves Prediction of Prognosis in Colorectal Cancer.Frontiers in genetics · 2021Article
- Improving the Prognosis of Colon Cancer through Knowledge-Based Clinical-Molecular Integrated Analysis.BioMed research international · 2021Article
- Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.Frontiers in immunology · 2021Review
- Article
- Bioactive phospho-therapy with black phosphorus forTheranostics · 2020Article
- An Efficient and Easy-to-Use Network-Based Integrative Method of Multi-Omics Data for Cancer Genes Discovery.Frontiers in genetics · 2020Article
- Predicting long-term multicategory cause of death in patients with prostate cancer: random forest versus multinomial model.American journal of cancer research · 2020Article
- LIME-based ensemble machine for predicting performance status of patients with liver cancer.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough many prognostic single-gene (SG) lists have been identified in cancer research, application of these features is hampered due to poor robustness and performance on independent datasets. Pathway-based approaches have thus emerged which embed biological knowledge to yield reproducible features.
methodsPathifier estimates pathways deregulation score (PDS) to represent the extent of pathway deregulation based on expression data, and most of its applications treat pathways as independent without addressing the effect of gene overlap between pathway pairs which we refer to as crosstalk. Here, we propose a novel procedure based on Pathifier methodology, which for the first time has been utilized with crosstalk accommodated to identify disease-specific features to predict prognosis in patients with hepatocellular carcinoma (HCC).
findingsWith the cohort (N = 355) of HCC patients from The Cancer Genome Atlas (TCGA), cross validation (CV) revealed that PDSs identified were more robust and accurate than the SG features by deep learning (DL)-based approach. When validated on external HCC datasets, these features outperformed the SGs consistently.
interpretationOn average, we provide 10.2% improvement of prediction accuracy. Importantly, governing genes in these features provide valuable insight into the cancer hallmarks of HCC. We develop an R package PATHcrosstalk (available from GitHub https://github.com/fabotao/PATHcrosstalk) with which users can discover pathways of interest with crosstalk effect considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.